

One Year Anniversary of the Sandwich Site

Since opening its Sandwich site just one year ago, Asymchem has flourished into a vibrant pharmaceutical innovation hub, employing over 100 skilled professionals and carrying forward a proud legacy of excellence and discovery.

The team has delivered multiple projects for clients in the first year through:

High Throughput Experimentation

Process and Analytical Chemistry

Continuous Flow Chemistry

Biotransformation Technologies

Leveraging expertise and sustainable technologies, plans are underway to expand R&D and manufacturing into:

Peptide

Oligonucleotide

Continuous Manufacturing

Larger-Scale Small Molecule Capacity

These milestones reflect Asymchem's commitment to smarter, greener solutions and its strategic vision for growth in the global market. The future at Sandwich looks bright, bold, and full of promise.

Peptide Solid-Phase Synthesizer Software Upgrade and Automation Progress

To overcome limitations in commercial peptide synthesizers, Asymchem began developing its peptide solid-phase synthesis platform in 2023, advancing reactor design, recipe software, and process control systems in parallel.

Recently, the platform's recipe software was upgraded to **version 5**, supporting multiple concentration functions and deprotection feed configurations.

Key technical advantages include:

PLC system for core equipment control

In-house formulation software for recipe control

DCS for coordinated response across workshop and tank areas

Fully automated solid-phase synthesis (excluding solid feeding)

Highly automated auxiliary workflows for preparation, solution mixing, transfer, and tank operations

Database and reporting system for comprehensive batch data capture and storage

Looking ahead, Asymchem will scale up automated peptide solid-phase synthesis capacity, improve equipment compatibility, and further advance PAT implementation to drive performance upgrades and iterative innovation.